Trade Agios Pharmaceuticals, Inc. - AGIO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.10 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Agios Pharmaceuticals Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 24.14 |
| Open* | 24.35 |
| 1-Year Change* | -12.54% |
| Day's Range* | 24.27 - 24.87 |
| 52 wk Range | 21.07-34.76 |
| Average Volume (10 days) | 297.30K |
| Average Volume (3 months) | 8.20M |
| Market Cap | 1.45B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 55.74M |
| Revenue | 20.15M |
| EPS | -3.80 |
| Dividend (Yield %) | N/A |
| Beta | 0.95 |
| Next Earnings Date | Nov 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 27, 2023 | 24.49 | 0.14 | 0.57% | 24.35 | 24.87 | 24.14 |
| Sep 26, 2023 | 24.14 | 0.16 | 0.67% | 23.98 | 24.97 | 23.98 |
| Sep 25, 2023 | 24.36 | 0.56 | 2.35% | 23.80 | 24.74 | 23.80 |
| Sep 22, 2023 | 24.47 | 0.31 | 1.28% | 24.16 | 24.87 | 24.16 |
| Sep 21, 2023 | 24.83 | 0.69 | 2.86% | 24.14 | 24.97 | 23.59 |
| Sep 20, 2023 | 24.51 | 0.20 | 0.82% | 24.31 | 25.17 | 24.31 |
| Sep 19, 2023 | 25.02 | 0.04 | 0.16% | 24.98 | 25.41 | 24.64 |
| Sep 18, 2023 | 25.40 | -0.51 | -1.97% | 25.91 | 26.39 | 25.30 |
| Sep 15, 2023 | 25.96 | 0.08 | 0.31% | 25.88 | 26.85 | 25.65 |
| Sep 14, 2023 | 26.83 | 0.38 | 1.44% | 26.45 | 27.58 | 26.45 |
| Sep 13, 2023 | 27.20 | 0.71 | 2.68% | 26.49 | 27.29 | 26.48 |
| Sep 12, 2023 | 27.07 | 0.85 | 3.24% | 26.22 | 27.39 | 26.22 |
| Sep 11, 2023 | 26.65 | 1.37 | 5.42% | 25.28 | 26.82 | 25.27 |
| Sep 8, 2023 | 26.06 | 0.47 | 1.84% | 25.59 | 26.16 | 25.42 |
| Sep 7, 2023 | 25.95 | -0.23 | -0.88% | 26.18 | 26.27 | 25.74 |
| Sep 6, 2023 | 26.51 | -0.15 | -0.56% | 26.66 | 26.93 | 26.24 |
| Sep 5, 2023 | 26.84 | 0.13 | 0.49% | 26.71 | 27.96 | 26.71 |
| Sep 1, 2023 | 28.10 | 1.46 | 5.48% | 26.64 | 28.44 | 26.63 |
| Aug 31, 2023 | 27.37 | 1.11 | 4.23% | 26.26 | 27.57 | 26.26 |
| Aug 30, 2023 | 27.21 | 0.59 | 2.22% | 26.62 | 27.29 | 26.24 |
Agios Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, November 1, 2023 | ||
| Time (UTC) 12:30 | Country US
| Event Q3 2023 Agios Pharmaceuticals Inc Earnings Release Q3 2023 Agios Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Wednesday, February 21, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 Agios Pharmaceuticals Inc Earnings Release Q4 2023 Agios Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 14.24 | 0 | 0 | 0 | 94.387 |
| Revenue | 14.24 | 94.387 | |||
| Total Operating Expense | 265.583 | 371.779 | 335.916 | 316.269 | 456.866 |
| Selling/General/Admin. Expenses, Total | 121.673 | 121.445 | 115.105 | 102.007 | 114.145 |
| Research & Development | 279.91 | 256.973 | 220.811 | 214.262 | 341.324 |
| Operating Income | -251.343 | -371.779 | -335.916 | -316.269 | -362.479 |
| Interest Income (Expense), Net Non-Operating | 12.793 | 0.836 | 6.611 | 14.861 | 16.451 |
| Net Income Before Taxes | -231.801 | -356.51 | -329.305 | -301.408 | -346.028 |
| Net Income After Taxes | -231.801 | -356.51 | -329.305 | -301.408 | -346.028 |
| Net Income Before Extra. Items | -231.801 | -356.51 | -329.305 | -301.408 | -346.028 |
| Net Income | -231.801 | 1604.71 | -327.37 | -411.472 | -346.028 |
| Total Adjustments to Net Income | |||||
| Income Available to Common Excl. Extra. Items | -231.801 | -356.51 | -329.305 | -301.408 | -346.028 |
| Income Available to Common Incl. Extra. Items | -231.801 | 1604.71 | -327.37 | -411.472 | -346.028 |
| Diluted Net Income | -231.801 | 1604.71 | -327.37 | -411.472 | -346.028 |
| Diluted Weighted Average Shares | 54.7894 | 60.4473 | 68.9979 | 59.9945 | 57.4183 |
| Diluted EPS Excluding Extraordinary Items | -4.23076 | -5.89786 | -4.77268 | -5.02392 | -6.02644 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -6.74409 | -6.00769 | -4.77268 | -5.02392 | -6.02644 |
| Total Extraordinary Items | 0 | 1961.22 | 1.935 | -110.064 | |
| Cost of Revenue, Total | 1.704 | 1.397 | |||
| Gross Profit | 12.536 | 92.99 | |||
| Unusual Expense (Income) | -137.704 | -6.639 | 0 | 0 | |
| Other, Net | 6.749 | 14.433 | 0 | 0 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 6.712 | 5.609 | 4.31 | 3.516 | 5.582 |
| Total Operating Expense | 100.412 | 96.222 | -24.371 | 90.163 | 100.518 |
| Selling/General/Admin. Expenses, Total | 30.409 | 28.367 | 32.771 | 29.123 | 28.264 |
| Research & Development | 68.895 | 67.301 | 70.298 | 64.966 | 74.523 |
| Operating Income | -93.7 | -90.613 | 28.681 | -86.647 | -94.936 |
| Interest Income (Expense), Net Non-Operating | 8.254 | 8.091 | 6.488 | 3.818 | 1.793 |
| Net Income Before Taxes | -83.806 | -81.018 | 36.526 | -81.747 | -91.806 |
| Net Income After Taxes | -83.806 | -81.018 | 36.526 | -81.747 | -91.806 |
| Net Income Before Extra. Items | -83.806 | -81.018 | 36.526 | -81.747 | -91.806 |
| Total Extraordinary Items | 0 | 0 | 0 | ||
| Net Income | -83.806 | -81.018 | 36.526 | -81.747 | -91.806 |
| Income Available to Common Excl. Extra. Items | -83.806 | -81.018 | 36.526 | -81.747 | -91.806 |
| Income Available to Common Incl. Extra. Items | -83.806 | -81.018 | 36.526 | -81.747 | -91.806 |
| Diluted Net Income | -83.806 | -81.018 | 36.526 | -81.747 | -91.806 |
| Diluted Weighted Average Shares | 55.6043 | 55.2654 | 54.9548 | 54.8446 | 54.7997 |
| Diluted EPS Excluding Extraordinary Items | -1.50718 | -1.46598 | 0.66465 | -1.49052 | -1.6753 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.50718 | -1.46598 | -1.66186 | -1.57153 | -1.72465 |
| Unusual Expense (Income) | 0 | 0 | -127.853 | -4.443 | -2.704 |
| Other, Net | 1.64 | 1.504 | 1.357 | 1.082 | 1.337 |
| Revenue | 6.712 | 5.609 | 4.31 | 3.516 | 5.582 |
| Cost of Revenue, Total | 1.108 | 0.554 | 0.413 | 0.517 | 0.435 |
| Gross Profit | 5.604 | 5.055 | 3.897 | 2.999 | 5.147 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 832.772 | 1064.23 | 636.677 | 611.704 | 613.78 |
| Cash and Short Term Investments | 783.119 | 1020.02 | 572.929 | 564.877 | 585.302 |
| Cash & Equivalents | 139.259 | 203.126 | 127.436 | 80.931 | 70.502 |
| Short Term Investments | 643.86 | 816.892 | 445.493 | 483.946 | 514.8 |
| Total Receivables, Net | 2.206 | 4.378 | 25.399 | 15.319 | 10.442 |
| Prepaid Expenses | 38.955 | 39.835 | 23.651 | 24.177 | 17.167 |
| Total Assets | 1238.72 | 1437.74 | 852.952 | 890.741 | 858.457 |
| Property/Plant/Equipment, Total - Net | 88.116 | 104.23 | 117.542 | 126.108 | 24.32 |
| Property/Plant/Equipment, Total - Gross | 138.186 | 149.204 | 158.895 | 158.22 | 50.472 |
| Accumulated Depreciation, Total | -50.07 | -44.974 | -41.353 | -32.112 | -26.152 |
| Long Term Investments | 313.874 | 266.375 | 97.608 | 152.929 | 220.119 |
| Other Long Term Assets, Total | 3.956 | 2.9 | 1.125 | 0 | 0.238 |
| Total Current Liabilities | 62.629 | 59.826 | 94.394 | 92.886 | 93.503 |
| Accounts Payable | 18.616 | 16.7 | 26.844 | 21.896 | 17.88 |
| Accrued Expenses | 44.013 | 42.795 | 67.233 | 59.784 | 42.147 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0 | 10.933 | 33.476 | |
| Total Liabilities | 137.904 | 145.761 | 453.452 | 250.213 | 170.92 |
| Total Long Term Debt | 0 | 0.276 | 0.331 | 0.673 | 0 |
| Other Liabilities, Total | 75.275 | 85.659 | 358.727 | 156.654 | 77.417 |
| Total Equity | 1100.81 | 1291.97 | 399.5 | 640.528 | 687.537 |
| Common Stock | 0.071 | 0.071 | 0.069 | 0.068 | 0.058 |
| Additional Paid-In Capital | 2386.32 | 2334.35 | 2242.8 | 2156.36 | 1794.28 |
| Retained Earnings (Accumulated Deficit) | -470.561 | -238.76 | -1843.47 | -1516.1 | -1104.63 |
| Other Equity, Total | -12.535 | -1.198 | 0.105 | 0.202 | -2.171 |
| Total Liabilities & Shareholders’ Equity | 1238.72 | 1437.74 | 852.952 | 890.741 | 858.457 |
| Total Common Shares Outstanding | 55.0397 | 54.3342 | 69.2939 | 68.4011 | 58.2187 |
| Accounts Receivable - Trade, Net | 2.206 | 21.328 | 11.852 | 7.31 | |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Total Inventory | 8.492 | 14.698 | 7.331 | 0.869 | |
| Current Port. of LT Debt/Capital Leases | 0 | 0.331 | 0.317 | 0.273 | |
| Capital Lease Obligations | 0 | 0.276 | 0.331 | 0.673 | |
| Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | |
| Other Current Assets, Total | 0 | ||||
| Treasury Stock - Common | -802.486 | -802.486 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 791.656 | 832.772 | 784.935 | 870.007 | 975.145 |
| Cash and Short Term Investments | 739.201 | 783.119 | 727.68 | 819.309 | 923.529 |
| Cash & Equivalents | 104.139 | 139.259 | 122.449 | 88.543 | 80.026 |
| Short Term Investments | 635.062 | 643.86 | 605.231 | 730.766 | 843.503 |
| Prepaid Expenses | 39.303 | 38.955 | 46.487 | 42.336 | 43.226 |
| Other Current Assets, Total | |||||
| Total Assets | 1151.3 | 1238.72 | 1180.32 | 1252.47 | 1335.86 |
| Property/Plant/Equipment, Total - Net | 83.959 | 88.116 | 93.13 | 97.66 | 101.978 |
| Long Term Investments | 271.727 | 313.874 | 298.352 | 280.845 | 255.836 |
| Other Long Term Assets, Total | 3.956 | 3.956 | 3.903 | 3.955 | 2.9 |
| Total Current Liabilities | 45.113 | 62.629 | 53.596 | 48.396 | 45.792 |
| Accounts Payable | 8.662 | 18.616 | 10.415 | 7.79 | 11.551 |
| Accrued Expenses | 36.451 | 44.013 | 43.098 | 40.439 | 31.491 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.083 | 0.167 | 0.25 | |
| Other Current Liabilities, Total | 2.5 | ||||
| Total Liabilities | 114.772 | 137.904 | 130.15 | 128.397 | 128.406 |
| Total Long Term Debt | 0 | 0 | 1.055 | 1.055 | 0.276 |
| Capital Lease Obligations | 0 | 1.055 | 1.055 | 0.276 | |
| Other Liabilities, Total | 69.659 | 75.275 | 75.499 | 78.946 | 82.338 |
| Total Equity | 1036.53 | 1100.81 | 1050.17 | 1124.07 | 1207.45 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.072 | 0.071 | 0.071 | 0.071 | 0.071 |
| Additional Paid-In Capital | 2398.93 | 2386.32 | 2374.75 | 2362.33 | 2351.15 |
| Retained Earnings (Accumulated Deficit) | -551.579 | -470.561 | -507.087 | -425.34 | -333.534 |
| Other Equity, Total | -8.411 | -12.535 | -15.083 | -10.502 | -7.745 |
| Total Liabilities & Shareholders’ Equity | 1151.3 | 1238.72 | 1180.32 | 1252.47 | 1335.86 |
| Total Common Shares Outstanding | 55.5414 | 55.0397 | 54.894 | 54.8154 | 54.7769 |
| Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
| Total Receivables, Net | 1.778 | 2.206 | 5.592 | 4.302 | 5.905 |
| Treasury Stock - Common | -802.486 | -802.486 | -802.486 | -802.486 | -802.486 |
| Accounts Receivable - Trade, Net | 1.778 | 2.206 | 1.818 | 1.598 | 0.54 |
| Total Inventory | 11.374 | 8.492 | 5.176 | 4.06 | 2.485 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -231.801 | 1604.71 | -327.37 | -411.472 | -346.028 |
| Cash From Operating Activities | -309.478 | -407.32 | -290.759 | -370.622 | -304.421 |
| Cash From Operating Activities | 8.564 | 9.24 | 9.984 | 8.087 | 7.172 |
| Non-Cash Items | -69.808 | -1984.45 | 97.664 | 78.762 | 69.54 |
| Cash Taxes Paid | |||||
| Changes in Working Capital | -16.433 | -36.822 | -71.037 | -45.999 | -35.105 |
| Cash From Investing Activities | 243.261 | 1248.78 | 75.746 | 91.44 | -273.825 |
| Capital Expenditures | -4.881 | -5.741 | -14.909 | -12.171 | -6.986 |
| Other Investing Cash Flow Items, Total | 248.142 | 1254.52 | 90.655 | 103.611 | -266.839 |
| Cash From Financing Activities | 2.35 | -765.768 | 261.518 | 289.611 | 546.024 |
| Financing Cash Flow Items | 0 | 0 | 250.537 | 0 | -0.391 |
| Issuance (Retirement) of Stock, Net | 2.681 | -765.19 | 11.317 | 289.724 | 546.415 |
| Net Change in Cash | -63.867 | 75.69 | 46.505 | 10.429 | -32.222 |
| Issuance (Retirement) of Debt, Net | -0.331 | -0.578 | -0.336 | -0.113 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -81.018 | -231.801 | -268.327 | -186.58 | -94.774 |
| Cash From Operating Activities | -95.183 | -309.478 | -243.315 | -171.964 | -97.735 |
| Cash From Operating Activities | 1.79 | 8.564 | 6.75 | 4.769 | 2.478 |
| Non-Cash Items | 9.821 | -69.808 | 46.013 | 32.986 | 19.096 |
| Changes in Working Capital | -25.776 | -16.433 | -27.751 | -23.139 | -24.535 |
| Cash From Investing Activities | 57.596 | 243.261 | 160.31 | 56.24 | -26.573 |
| Capital Expenditures | -0.399 | -4.881 | -4.768 | -4.73 | -2.804 |
| Other Investing Cash Flow Items, Total | 57.995 | 248.142 | 165.078 | 60.97 | -23.769 |
| Cash From Financing Activities | 2.467 | 2.35 | 2.328 | 1.141 | 1.208 |
| Issuance (Retirement) of Stock, Net | 2.467 | 2.681 | 2.576 | 1.305 | 1.289 |
| Issuance (Retirement) of Debt, Net | 0 | -0.331 | -0.248 | -0.164 | -0.081 |
| Net Change in Cash | -35.12 | -63.867 | -80.677 | -114.583 | -123.1 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Agios Pharmaceuticals, Inc. Company profile
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Agios Pharmaceuticals Inc revenues was not reported. Net loss before extraordinary items increased 8% to $356.5M. Higher net loss reflects Research and development increase of 20% to $232.4M (expense), General and administrative increase of 15% to $92.5M (expense), Interest Income decrease of 87% to $836K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$4.77 to -$5.90.
Equity composition
Common Stock $.001 Par, Shares auth and O/s after the offering: 78.3 M auth., 29,380,399 issd. Insider Owns approx.38.04%.(After the IPO) IPO:TBA.
| Industry: | Bio Therapeutic Drugs |
88 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com